Fgfr2 inhibitor patent landscape
WebAlofanib (RPT835) is a novel selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). We showed previously that alofanib could bind to the extracellular domain of FGFR2 and has an inhibitory effect on FGF2-induced phoshphorylation of FRS2α. In the present study, we further show … WebCROSS-REFERENCE TO RELATED APPLICATIONS. This application claims the benefit of U.S. Provisional Application No. 62/846,991, filed on May 13, 2024; U.S. Provisional Application No
Fgfr2 inhibitor patent landscape
Did you know?
WebDec 3, 2024 · The current landscape of FGFR inhibitors includes small-molecule receptor TKIs (non-selective, selective and covalent), monoclonal antibodies, FGF ligand traps and DNA/RNA aptamers. We would like to show you a description here but the site won’t allow us. WebApr 1, 2024 · FGFR inhibitors target these receptor alterations and show promise as a drug class. Currently 2 medications are currently FDA approved: erdafitinib and pemigatinib.
WebMar 13, 2024 · Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor. We report safety and preliminary efficacy from the first-in-human phase 1b study of alofanib in heavily pretreated patients with advanced gastric cancer. The standard dose-escalation design 3+3 aimed to establish the maximum tolerated dose (MTD) or recommended … WebJan 4, 2024 · RLY-4008 is a potent and selective oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in many cancers, including cholangiocarcinoma, breast cancer ...
WebFeb 21, 2024 · No reports of FGFR2-CTNNA3 fusion in association with a high-grade or aggressive tumor have been made to date. However, it is important to note that while FGFR2-CTNNA3 appears to be relatively specific signature of PLNTY, the molecular landscape of PLNTY includes genetic abnormalities involving either BRAF or even … WebMar 18, 2024 · Clinicopathological landscape of patients exhibiting FGFR2 fusion among all types of cancer. (a) Venn diagram showing the percentage distribution of tumor types with FGFR2 fusion (15 cases): GC (46.7%), …
WebFibroblast growth factor receptor 2 ( FGFR2) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. 8-10 Two selective FGFR1–3 inhibitors, pemigatinib... camping le bocage valognesWebFeb 21, 2024 · Development of a class of targeted therapies called FGFR inhibitors, which target FGFR2 fusions and rearrangements, have produced significant responses in … camping le blayais alicat saint georgesWebFGF-2 Inhibitors. Fibroblast growth factor-1 (FGF-1), also designated acidic FGF, and fibroblast growth factor-2 (FGF-2), also designated basic FGF, are members of a family … firth 25 seriesWebembodiment, the FGFR inhibitor is erdafitinib. [0049] Disclosed herein is a FGFR inhibitor for use in the treatment of cholangiocarcinoma in a patient harboring the FGFR2 SNP C383R. The... firth 3 sheffieldWebAreas covered: This review summarizes patent and literature publications spanning from 2015 to 2024 pertaining to small-molecule FGFR kinase inhibitors. Expert opinion: The … firth 20 seriesWebcompetitive selective inhibitor of FGFR1, FGFR2, and FGFR3 with half maximal inhibitor concentration (IC50) values of 0.4, 0.4, and 1nmol/l, respectively, with weaker inhibition of FGFR4. Pemigatinib is highly selective for FGFR but has been shown to have mild inhibitor effects on vascular endothelial growth factor receptor 2 camping le bohat sarzeauWebOct 9, 2024 · In this article, we discuss the biological rationale for FGFR2 targeting, thoroughly review the preclinical and clinical development of FGFR2 inhibitors, and … firth 6 northern general hospital